Key Drivers
- Strong Liquidity
- Ongoing Losses
- Equity Dilution
AIAI Summary
GHRS is a well-funded but high-expectation clinical option on GH001: its $363M cash balance supports Phase 3 execution without near-term financing pressure, but the ~$2.1B valuation depends on positive efficacy, safety, and drug-device execution rather than current operations. Investors should view Phase 3 progress in treatment-resistant depression as the decisive catalyst and avoid treating FDA planning alignment as clinical validation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Ongoing Losses
- •Equity Dilution
GHRS is well-capitalized with minimal debt, but persistent losses, negative cash flow, no revenue, and share dilution make its investment case dependent on future clinical and commercial progress.
Price Behavior
Key Price Behavior Insights:
- •Late-August rebound
- •Neutral momentum
- •Resistance overhead
GHRS is holding modest support near $28.00 after its late-August rebound, but needs to clear $28.70–$29.10 to strengthen while a break below $27.00–$27.20 raises downside risk.
Rebounded from $26.98 in late
Sentiment & News
Similar Companies in Healthcare
Other companies in the same sector with AI ratings